Leonard Zehr, Author at BioTuesdays

Developments

Theralase to present Phase 2 NMIBC interim data at AUA meeting

The American Urology Association has accepted for a moderated poster presentation at its annual meeting Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) interim data from its Phase 2 Bacillus Calmette Guerin unresponsive...

February 2, 2023

Feature

Stephanie Willerth talks up award winning bioink start-up

As CEO and co-founder of closely-held Axolotl Biosciences, Stephanie Willerth, Ph.D., also is a full professor of biomedical engineering at the University of Victoria, British Columbia, where she runs a research lab...

January 31, 2023

Feature

Azura targeting ophthalmic keratolytics for ocular surface diseases

After posting positive Phase 2b results in November, Azura Ophthalmics plans to launch a Phase 3 registration trial in mid-2023 with its lead ointment, AZR-MD-001, for the treatment of meibomian gland dysfunction (MGD)...

January 24, 2023

Developments

Hepion posts positive preclinical results in multiple myeloma expanding rencofilstat’s anti-cancer potential

Hepion Pharmaceuticals (NASDAQ:HEPA) announced positive results of preclinical studies examining rencofilstat as a potential therapeutic for multiple myeloma (MM). Rencofilstat exerted anti-cancer activity across a...

January 18, 2023

Feature

Reneo targeting rare genetic mitochondrial diseases with unmet need

Reneo Pharmaceuticals (NASDAQ:RPHM) is conducting a pivotal Phase 2b clinical trial with its lead asset, REN001, in a rare genetic disease that predominately affects skeletal muscle and reduces life expectancy, with...

January 17, 2023

Executive Moves

Raymond James adds 3 senior bankers to healthcare practice

Raymond James Ltd. (CNW Group/Raymond James Ltd.) Raymond James again expanded its healthcare investment banking practice with the addition of three senior bankers. Joining the firm as managing directors are Jeff...

January 12, 2023

Feature

SeaStar Medical gears for Q1 FDA decision on device to reverse effects of hyperinflammation

SeaStar Medical (NASDAQ:ICU) expects an FDA decision in the first quarter on a humanitarian device exemption application to use its Selective Cytopheretic Device (SCD) to treat the life-threatening effects of...

January 10, 2023

Developments

Hepion Pharmaceuticals receives non-dilutive funding

Hepion Pharmaceuticals (NASDAQ:HEPA) received $2.9-million in net proceeds from the sale of tax benefits under the company’s participation in the New Jersey Economic Development Authority (NJEDA) net operating loss...

January 9, 2023

Developments

Hepion to present Phase 2a rencofilstat multiomics data at NASH-TAG 2023

Hepion Pharmaceuticals (NASDAQ:HEPA) will present an abstract highlighting its lead drug candidate, rencofilstat, at the NASH-TAG 2023 Conference in Park City, Utah on Jan. 7. The presentation is entitled, “Rencofilstat...

January 6, 2023

Developments

iBio receives U.S. patent for AI-engineered epitope discovery engine

iBio (NYSEA:IBIO) received a patent from the U.S. Patent and Trademark Office issued a patent entitled, “Machine Learning Method For Protein Modelling To Design Engineered Peptides,” which covers a machine learning...

January 5, 2023

Author - Leonard Zehr

Theralase to present Phase 2 NMIBC interim data at AUA meeting

Stephanie Willerth talks up award winning bioink start-up

Azura targeting ophthalmic keratolytics for ocular surface diseases

Hepion posts positive preclinical results in multiple myeloma expanding rencofilstat’s anti-cancer potential

Reneo targeting rare genetic mitochondrial diseases with unmet need

Raymond James adds 3 senior bankers to healthcare practice

SeaStar Medical gears for Q1 FDA decision on device to reverse effects of hyperinflammation

Hepion Pharmaceuticals receives non-dilutive funding

Hepion to present Phase 2a rencofilstat multiomics data at NASH-TAG 2023

iBio receives U.S. patent for AI-engineered epitope discovery engine

General

More